Trial Profile
A retrospective, interventional, consecutive case series study to evaluate one year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 05 Dec 2015 New trial record